Faricimab Outperforms High-Dose Aflibercept in Fluid Reduction at 12 Weeks

(MedPage Today) -- Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched analyses of diabetic macular edema (DME) and age-related macular degeneration (AMD) studies presented at the...